VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report published on Friday morning. The firm issued a sell rating on the stock.

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Performance

NYSE:VNRX opened at $0.63 on Friday. The stock has a market capitalization of $58.29 million, a price-to-earnings ratio of -1.75 and a beta of 1.17. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The stock has a fifty day moving average price of $0.69 and a two-hundred day moving average price of $0.67.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the SEC. 8.09% of the stock is owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.